Pharmacokinetics in Serum and Leukocyte Exposures of Oral Azithromycin, 1,500 Milligrams, Given over a 3- or 5-Day Period in Healthy Subjects

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  1999-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.43.1.163PMID 9869584PMCID PMC89039
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of Oral Azithromycin in Serum, Urine, Polymorphonuclear Leucocytes and Inflammatory vs Non-Inflammatory Skin Blisters in Healthy Volunteers

  1998cited by this paper
• Comparison of the Plasma, Urine and Blister Fluid Pharmacokinetics of Clarithromycin and Azithromycin in Normal Subjects

  1997cited by this paper
• Expanding indications for the new macrolides, azalides, and streptogramins.

  1997cited by this paper
• Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses

  1996cited by this paper
• Erythromycin, clarithromycin, and azithromycin: are the differences real?

  1996cited by this paper
• TopFit: a PC-based pharmacokinetic/pharmacodynamic data analysis program.

  1993cited by this paper
• Comparison of the pharmacokinetics of three-day and five-day regimens of azithromycin in plasma and urine.

  1993cited by this paper
• Selection of dose regimens of azithromycin .

  1993cited by this paper
• Azithromycin: The First Azalide Antibiotic

  1992cited by this paper
• Pharmacokinetics of azithromycin in rats and dogs.

  1990cited by this paper
• Intracellular accumulation of azithromycin by cultured human fibroblasts

  1990cited by this paper
• The pharmacokinetics of azithromycin in human serum and tissues.

  1990cited by this paper
• Mean cell volume of human blood leucocytes and resident and activated murine macrophages.

  1990cited by this paper
• Azithromycin concentrations at the sites of pulmonary infection.

  1990cited by this paper
• Interaction of azithromycin and human phagocytic cells. Uptake of the antibiotic and the effect on the survival of ingested bacteria in phagocytes.

  1989cited by this paper
• In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection

  1989cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• PBPK Modeling of Azithromycin Systemic Exposure in a Roux-en-Y Gastric Bypass Surgery Patient Population

  2023cites this paper
• Background review for the ‘2020 European guideline for the diagnosis and treatment of gonorrhoea in adults’

  2020cites this paper
• 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults.

  2020cites this paper
• Azithromycin Pharmacodynamics Against Non-Typeable H. Influenzae

  2019cites this paper
• Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review

  2019cites this paper
• Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated Salmonella Typhi infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model

  2019cites this paper
• Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease

  2017cites this paper
• Is the current treatment of urogental and anorectal chlamydia infection appropriate

  2017cites this paper
• Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia

  2016cites this paper
• Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease

  2016cites this paper
• Treatment of rectal chlamydia infection may be more complicated than we originally thought.

  2014cites this paper
• Macrolides and Ketolides

  2014cites this paper
• Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics

  2014cites this paper
• Development of a Population Pharmacokinetic Model Characterizing the Tissue Distribution of Azithromycin in Healthy Subjects

  2014cites this paper
• Pharmacokinetics and Pharmacodynamics of Anti-infective Agents

  2014cites this paper
• Population Pharmacokinetics of Azithromycin in Whole Blood, Peripheral Blood Mononuclear Cells, and Polymorphonuclear Cells in Healthy Adults

  2014cites this paper
• Efficacy of azithromycin in preventing lethal graft‐versus‐host disease

  2013cites this paper
• Current Trachoma Treatment Methodologies

  2012cites this paper
• Influence of Body Weight, Ethnicity, Oral Contraceptives, and Pregnancy on the Pharmacokinetics of Azithromycin in Women of Childbearing Age

  2012cites this paper
• Macrolides and Ketolides

  2012cites this paper
• Macrolides for the treatment of chronic bacterial prostatitis: an effective application of their unique pharmacokinetic and pharmacodynamic profile (Review).

  2011influential citation
• Bullous Oral Eruptions Caused by Azithromycin

  2011cites this paper
• Influence of Body Weight, Ethnicity, Oral Contraceptives and Pregnancy on the Pharmacokinetics of Azithromycin in Women of Child-Bearing Age Running Title: Pharmacokinetics of Azithromycin in Pregnancy

  2011cites this paper
• Influence of Body Weight, Ethnicity, Oral Contraceptives, and Pregnancy on the Pharmacokinetics of Azithromycin in Women of Childbearing Age

  2011cites this paper
• Oralna bulozna erupcija uzrokovana azitromicinom Bullous Oral Eruptions Caused by Azithromycin

  2011cites this paper
• Efficacy and Safety of Short-Duration Topical Treatment with Azithromycin Oil-Based Eyedrops in an Experimental Model of Corneal Refractive Surgery

  2010cites this paper
• Ocular Pharmacokinetics of AzaSite Xtra—2% Azithromycin Formulated in a DuraSite Delivery System

  2009cites this paper
• Ketolides — The Modern Relatives of Macrolides

  2009cites this paper
• Comparison of Ceftriaxone Plus Weekly Azithromycin or Daily Ofloxacin for Outpatient Treatment of Pelvic Inflammatory Disease: a randomized clinical trial

  2008cites this paper
• Use of azithromycin in the treatment of acute exacerbations of COPD

  2008cites this paper
• Azitromicin u liječenju akutnih egzacerbacija kronične opstruktivne plućne bolesti

  2008cites this paper
• Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.

  2007cites this paper
• Clinical Pharmacokinetics and Gastrointestinal Tolerability of a Novel Extended-Release Microsphere Formulation of Azithromycin

  2007cites this paper
• Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers.

  2007cites this paper
• Novel, single-dose microsphere formulation of azithromycin extended-release for the treatment of respiratory tract infections

  2006cites this paper
• Comparative Pharmacokinetics of Azithromycin in Serum and White Blood Cells of Healthy Subjects Receiving a Single-Dose Extended-Release Regimen versus a 3-Day Immediate-Release Regimen

  2006cites this paper
• Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection

  2006cites this paper
• [Clinical trial of chemotherapy identified according to chemosensitivity assay for oral cancer patients with unresectable recurrent lesions].

  2006cites this paper
• "Novel applications of DDS on infectious diseases and future prospect" Perspective of DDS in treatment of respiratory tract infection

  2006cites this paper
• Absolute Bioavailability and Intracellular Pharmacokinetics of Azithromycin in Patients with Cystic Fibrosis

  2005cites this paper
• Azithromycin and lower respiratory tract infections

  2005cites this paper
• Treatment of acute exacerbation of severe-to-very severe COPD with azithromycin in patients vaccinated against Streptococcus pneumoniae.

  2005cites this paper
• The Disease-Modifying Effects of Twice-Weekly Oral Azithromycin in Patients with Bronchiectasis

  2005cites this paper
• Once-Daily Azithromycin for 3 Days Compared with Clarithromycin for 10 Days for Acute Exacerbation of Chronic Bronchitis

  2005cites this paper
• Novi pogled na primjenu azitromicina u liječenju spolno prenosivih infekcija

  2004cites this paper
• Determination of the Lack of a Drug Interaction Between Azithromycin and Warfarin

  2004cites this paper
• Single-Dose Azithromycin for Respiratory Tract Infections

  2004cites this paper
• Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis.

  2003cites this paper
• Efficacy and Safety of Azithromycin as Monotherapy or Combined with Metronidazole Compared with Two Standard Multidrug Regimens for the Treatment of Acute Pelvic Inflammatory Disease

  2003cites this paper
• Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects.

  2002cites this paper
• Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers.

  2002cites this paper
• Current trachoma treatment methodologies: focus on advancements in drug therapy.

  2002cites this paper
• Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers.

  2001cites this paper
• Use of Anti-Infective Agents During Lactation: Part 2—Aminoglycosides, Macrolides, Quinolones, Sulfonamides, Trimethoprim, Tetracyclines, Chloramphenicol, Clindamycin, and Metronidazole

  2001cites this paper
• Macrolides: pharmacokinetics and pharmacodynamics.

  2001cites this paper
• Azithromycin: indications for the future?

  2000cites this paper
• Chapter 13. Progress in macrolide and ketolide antibacterials

  2000cites this paper
• Comparison of the Serum and Intracellular Pharmacokinetics of Azithromycin in Healthy and Diabetic Volunteers

  2000cites this paper